Value to Strategic Partners

Published on May 2016 | Categories: Documents | Downloads: 35 | Comments: 0 | Views: 243
of 23
Download PDF   Embed   Report

https://www.scribd.com/doc/258128455/Value-to-Strategic-Partners1

Comments

Content

HealthiosXchange Value to the
Strategic Partner

BIOPHARMACEUTICALS

MEDTECH & DIAGNOSTICS

Cardiovascular Devices
Prosthetic Heart Valve
Peripheral Vascular Devices
Cardiovascular Monitoring & Diagnostic Devices
Cardiovascular Surgery
Cardiac Rhythm Management
Cardiovascular Prosthetic Devices
Interventional Cardiology
Cardiac Assist Devices
Wound Care Management
Hospital Supplies
Syringes and Needles
Disposable Hospital & Surgical Supplies
Drug Delivery Devices
Inhalation Systems
Needle Free Injections
Infusion Systems
Diabetes Care Devices
Insulin Delivery & Glucose Monitoring
Ophthalmic Devices
Cataract Surgery Devices
Ophthalmic Diagnostic Equipment
Refractive Surgery Devices
ENT Devices
Hearing Implants
Diagnostic Devices
Electrosurgical Devices
Dental Equipment & Accessories
Diagnostic Imaging & MRI Systems
C/T Systems & Mammography Equipment
X-Ray & Ultrasound Systems
Nuclear Imaging Equipment
Contrast Media Injectors
Bone Densitometry
Anesthesia and Respiratory Devices
Anesthesia Machines & Disposables
Respiratory Devices & Disposables
Sleep Apnea Diagnostic Systems
Healthcare IT
Medical Imaging Information Systems
Nephrology and Urology Devices
Renal Dialysis Equipment
Orthopedic Devices
Orthobiologics & Arthroscopy
Joint Reconstruction
Trauma Fixation
Orthopedic Prosthetics
Cranium Maxillofacial Fixation (CMF)
Spinal Surgery
Endoscopy Devices & instruments
Rigid & Flexible Endoscope
In Vitro Diagnostics
Genetic Testing
Clinical Chemistry
Hematology
Immuno Chemistry
Infectious Immunology
Histology And Cytology
Patient Monitoring
Multiparameter Patient Monitoring
Micro-Electromechanical Systems
Non-invasive Blood Pressure Monitors
Neurology Devices
Neurostimulation Devices
Interventional Neurology
CSF Management
Neurosurgical Products
Radiosurgery

Diabetic Nephropathy
Diabetic Retinopathy
Hypercholesterolemia
Oral Mucositis
Gout
Acute Lymphocytic Leukemia
Bone Metastasis
Brain Cancer
Breast Cancer
Cervical Cancer
Chronic Lymphocytic Leukemia
Endometrial Cancer
Ewing Sarcoma
Gastric Cancer
Gastrointestinal Stromal Tumors
Head And Neck Cancer
Hodgkin Lymphoma
Kidney Cancer
Liver Cancer
Malignant Mesothelioma
Medullary Thyroid Cancer
Melanoma
Multiple Myeloma
Non-Hodgkin Lymphoma
Non-Small Cell Lung Cancer
Ovarian Cancer
Pancreatic Cancer
Testicular Cancer
Thyroid Cancer
Age Related Macular Degeneration
Keratoconjunctivitis sicca (Dry Eye)
Retinal Vein Occlusion
Acute Respiratory Distress
Syndrome
Sepsis
Staphylococcal Infections
Acute Coronary Syndrome
Angina Pectoris
Atrial Fibrillation
Coronary Artery Disease (CAD)
Critical Limb Ischemia
Hypertension
Pulmonary Arterial Hypertension
Acute Pain
Anxiety Disorders
Chronic Pain
Dementia
Diabetic Neuropathy
Obsessive-Compulsive Disorder
Osteoarthritis Pain
Parkinson's Disease
Post-Traumatic Stress Disorder
Restless Legs Syndrome
Schizophrenia
Traumatic Brain Injury
Liver Cirrhosis
Childhood Enuresis
Growth Hormone Disorders
Hyperparathyroidism
Hyperthyroidism
Guillain-Barre Syndrome
Cytomegalovirus
Fungal Infections
Gram-Negative Bacterial Infections
H1N1 Infection
Herpes Zoster
HIV-1 Infection
Human Papillomavirus Infections
Staphylococcus Aureus (MRSA)

Healthios Global Resources
Healthios’ investment research, capital markets & corporate finance team is wellpositioned worldwide to assist in optimizing the Company’s most important
financing and strategic objectives

Chicago, Illinois

David
David B.
B. Loucks
Loucks
Chairman
Chairman &
& CEO
CEO

Fritz
Fritz Reichenbach
Reichenbach
Managing
Managing Member
Member

Christoph
Christoph Brandenberger
Brandenberger
Managing
Managing Director
Director

Victor
Victor Culiuc
Culiuc
Managing
Managing Director
Director

Andrew
Andrew Romer
Romer
Analyst
Analyst

Kimberly
Kimberly Szokol
Szokol
Analyst
Analyst

David
David Donnelly
Donnelly
Director
Institutional
Director Institutional Sales
Sales

Deborah
Deborah Herst
Herst
Vice
President
Marketing
Vice President Marketing

Scott
Scott Jordan
Jordan
Vice
Vice President
President
HealthiosXchange
HealthiosXchange

Greg
Greg Shearer
Shearer
Managing
Managing Director
Director

Boston, Massachusetts

Ellen
Ellen Baron
Baron
Managing
Managing Director
Director

Bangkok, Thailand

Jane
Jane Phornprapha
Phornprapha
Vice
Vice President
President

Vichaya
Vichaya Hanpiyavatanasakul
Hanpiyavatanasakul
Sr.
Sr.Analyst
Analyst

Gun
Gun Punyacharoensin
Punyacharoensin
Analyst
Analyst

Pollaratch
Pollaratch Wanichakul
Wanichakul
Analyst
Analyst

Kasama
Kasama Limpanukorn
Limpanukorn
Analyst
Analyst

Jessica
Jessica Liang
Liang
Research
Research Analyst
Analyst

2

Healthios Experience
Transaction Closes since Q3 2013

Fujifilm Diosynth acquires 49% of the total
membership interests in Kalon

THE UNDERSIGNED ACTED AS EXCLUSIVE
ADVISOR TO KALON

CORIUM INTERNATIONAL, INC.,

DICERNA PHARMACEUTICALS, INC.
Has completed its $60,000,000
Series C Financing

$52,000,000
Initial Public Offering`

THE UNDERSIGNED ACTED AS EXCLUSIVE
ADVISOR TO DICERNA

THE UNDERSIGNED ACTED AS EXCLUSIVE
THE UNDERSIGNED
ACTED
AS FINANCIAL
ADVISOR TO ALINE
AESTHETICS
ADVISOR TO CORIUM

NANOMIX, INC.
Has completed its $12,000,000
Equity financing by strategic and
financial investors
THE UNDERSIGNED ACTED AS EXCLUSIVE
ADVISOR TO NANOMIX

ALINE
AESTHETICS
MIACOM DIAGNOSTICS
Has completed its equity financing from

THE UNDERSIGNED ACTED AS EXCLUSIVE
ADVISOR TO MIACOM MEDICAL SOLUTIONS

WELLFOUNT CORP.

CLEAR VASCULAR, INC.

Has completed its $22,000,000 Debt
and Equity financing

Completed a $6MM financing from an
Undisclosed Institutional Investor and
Family Offices
THE UNDERSIGNED ACTED AS EXCLUSIVE
ADVISOR TO CLEAR VASCULAR

THE UNDERSIGNED ACTED AS EXCLUSIVE
ADVISOR TO WELLFOUNT

3

a wholly owned subsidiary of
Has been acquired by

Healthios Experience
Transaction Closes since Q3 2013 (cont)

CARDIOSOUTIONS, INC.
CRITICAL PERFUSION, INC.
Has entered into a co-development
agreement with

IRX Therapeutics

Has completed its $15MM Series B
Round of Financing led by

Has completed a round of financing

THE UNDERSIGNED ACTED AS EXCLUSIVE
ADVISOR TO CLEARCOUNT MEDICAL SOLUTIONS

ORTHOCON, INC.

THE UNDERSIGNED ACTED AS ADVISOR
TO IRX

THE UNDERSIGHED ACTED AS EXCLUSIVE
ADVISOR TO CARDIOSOLUTIONS

ENVISIA THERAPEUTICS, INC.

VENTUS MEDICAL, INC.

Has completed a comprehensive
review of strategic & financial
alternatives

Has been acquired by

Has completed a $25,000,000 Series
A Financing in conjunction with the
“spin –off” of certain assets and
sciences from Liquidia

THE UNDERSIGNED ACTED AS STRATEGIC
ADVISOR TO ORTHOCON

THE UNDERSIGNED ACTED AS EXCLUSIVE
ADVISOR TO VENTUS MEDICAL

THE UNDERSIGNED ACTED AS EXCLUSIVE
ADVISOR TO LIQUIDIA

4

EXAGEN DIAGNOSTICS, INC.
Has completed its $25,000,000
Debt financing
THE UNDERSIGNED ACTED AS EXCLUSIVE
ADVISOR TO EXAGEN DIAGNOSTICS

Selected Current Clients

Confidential

5

Cardiovascular Devices
Prosthetic Heart Valve
Peripheral Vascular Devices
Cardiovascular Monitoring & Diagnostic Devices
Cardiovascular Surgery
Cardiac Rhythm Management
Cardiovascular Prosthetic Devices
Interventional Cardiology
Cardiac Assist Devices
Wound Care Management
Hospital Supplies
Syringes and Needles
Disposable Hospital & Surgical Supplies
Drug Delivery Devices
Inhalation Systems
Needle Free Injections
Infusion Systems
Diabetes Care Devices
Insulin Delivery & Glucose Monitoring
Ophthalmic Devices
Cataract Surgery Devices
Ophthalmic Diagnostic Equipment
Refractive Surgery Devices
ENT Devices
Hearing Implants
Diagnostic Devices
Electrosurgical Devices
Dental Equipment & Accessories
Diagnostic Imaging & MRI Systems
C/T Systems & Mammography Equipment
X-Ray & Ultrasound Systems
Nuclear Imaging Equipment
Contrast Media Injectors
Bone Densitometry
Anesthesia and Respiratory Devices
Anesthesia Machines & Disposables
Respiratory Devices & Disposables
Sleep Apnea Diagnostic Systems
Healthcare IT
Medical Imaging Information Systems
Nephrology and Urology Devices
Renal Dialysis Equipment
Orthopedic Devices
Orthobiologics & Arthroscopy
Joint Reconstruction
Trauma Fixation
Orthopedic Prosthetics
Cranium Maxillofacial Fixation (CMF)
Spinal Surgery
Endoscopy Devices & instruments
Rigid & Flexible Endoscope
In Vitro Diagnostics
Genetic Testing
Clinical Chemistry
Hematology
Immuno Chemistry
Infectious Immunology
Histology And Cytology
Patient Monitoring
Multiparameter Patient Monitoring
Micro-Electromechanical Systems
Non-invasive Blood Pressure Monitors
Neurology Devices
Neurostimulation Devices
Interventional Neurology
CSF Management
Neurosurgical Products
Radiosurgery

Click to edit Master text styles
Healthios Founders
David B. Loucks

David Loucks is Chairman and Chief Executive of Healthios. Throughout his career, Mr.
Loucks has been an advisor, financier, and general manager throughout the healthcare
industry, in the process nurturing an experienced perspective on capital markets,
development cycles and value creation. Prior to co-founding Healthios in 2007, Mr.
Loucks, was the founder and Managing Partner of the Aethena Group, LLC., a private
equity partnership with a broad portfolio of investment interests. From 1998 until 2001,
Mr. Loucks served as President and CEO of Physician Dynamics, Inc. (“PDI”), a fullyintegrated provider of technology-enabled care management solutions for patients
afflicted with chronic and acute diseases. In September 2000, PDI was sold to Landacor, a
publicly-traded healthcare information technology company. Prior to Physician Dynamics,
from 1994 through 1998, Mr. Loucks was a Vice President with Robertson, Stephens &
Company, a global investment banking firm. Among his duties at Robertson Stephens, Mr.
Loucks was a founder of the Special Situations practice and he directed that firm’s first
international financing initiatives for companies based in Europe, Israel, India, and China.
Mr. Loucks holds a BA from Yale University and an MBA from Northwestern. As a rower,
Mr. Loucks is a former National Champion.

 Click to edit Master text styles
 Second level

Managing Director
President and CEO
Direct: (847) 400-5000
Email: [email protected]

Fritz Reichenbach

Managing Director
Direct: (847) 849-1775
Email: [email protected]

Diabetic Nephropathy
Diabetic Retinopathy
Hypercholesterolemia
Oral Mucositis
Gout
Acute Lymphocytic Leukemia
Bone Metastasis
Brain Cancer
Breast Cancer
Cervical Cancer
Chronic Lymphocytic Leukemia
Endometrial Cancer
Ewing Sarcoma
Gastric Cancer
Gastrointestinal Stromal Tumors
Head And Neck Cancer
Hodgkin Lymphoma
Kidney Cancer
Liver Cancer
Malignant Mesothelioma
Medullary Thyroid Cancer
Melanoma
Multiple Myeloma
Non-Hodgkin Lymphoma
Non-Small Cell Lung Cancer
Ovarian Cancer
Pancreatic Cancer
Testicular Cancer
Thyroid Cancer
Age Related Macular Degeneration
Keratoconjunctivitis sicca (Dry Eye)
Retinal Vein Occlusion
Acute Respiratory Distress
Syndrome
Sepsis
Staphylococcal Infections
Acute Coronary Syndrome
Angina Pectoris
Atrial Fibrillation
Coronary Artery Disease (CAD)
Critical Limb Ischemia
Hypertension
Pulmonary Arterial Hypertension
Acute Pain
Anxiety Disorders
Chronic Pain
Dementia
Diabetic Neuropathy
Obsessive-Compulsive Disorder
Osteoarthritis Pain
Parkinson's Disease
Post-Traumatic Stress Disorder
Restless Legs Syndrome
Schizophrenia
Traumatic Brain Injury
Liver Cirrhosis
Childhood Enuresis
Growth Hormone Disorders
Hyperparathyroidism
Hyperthyroidism
Guillain-Barre Syndrome
Cytomegalovirus
Fungal Infections
Gram-Negative Bacterial Infections
H1N1 Infection
Herpes Zoster
HIV-1 Infection
Human Papillomavirus Infections
Staphylococcus Aureus (MRSA)

• Third level

– Fourth level
» Fifth level

Fritz Reichenbach is a Managing Member and Co-Founder of Healthios Capital
Markets, LLC. His corporate finance focus has primarily been on in vitro diagnostics,
blood products, and nuclear medicine. Mr. Reichenbach joined a Healthios affiliate,
the Aethena Group (a private equity partnership) as Vice President in September of
2001. Prior to joining Aethena, Fritz served as CFO for a healthcare-staffing firm and
a patient education and disease management company. Previous to his CFO roles
Fritz was a Partner at Central Europe Trust (CET), the largest advisory firm
specializing in Central and Eastern Europe. During Fritz’s tenure at CET, the firm
generated $120M in revenue, closed 50 significant M&A transactions, and raised and
managed $400M in private equity. Fritz started his career at Andersen Consulting
(“Accenture”). Fritz is a graduate of Yale University and holds a Masters of
Management from the Kellogg Graduate School of Management Managing Director
at Northwestern University.

Managing Directors
Healthios’s core team represents a unique assembly of experienced professionals, dedicated to
value creation within their client companies throughout the development cycle.

Christoph Brandenberger
Responsible for the
Cardiovascular Sector within
Healthios
Deal execution experience
across all healthcare sectors
Advised a diverse universe of
clients on M&A and financing
assignments, including mergers,
acquisitions, commercialization
and partnering agreements as
well as private placements
Extensive operational
experience working for a
European multinational
company
Previously with Montgomery
Securities in the Equity and
M&A Investment Banking
Group
University of Vienna, Austria;
MBA

Ellen Baron, Ph.D.

Greg Shearer

Goucher College; BA
Georgetown University School
of Medicine, Ph.D., Microbiology
Schering Plough Corporation
• 8 major agreements
• $2 billion annual
revenue/R&D effort
SVP, Bus. Dev., Human Genome
Sciences - Directed all
M&A/licensing
Partner, Oxford Bioscience
Partners
• $1 billion portfolio of 149
companies
• Board roles at: BrainCells,
Tragara, Claros, VaxInnate
Affinium, Intrapace, Applied
Spine Radius Health, Critical
Therapeutics

Centre College; BA
University of Chicago; MBA
Senior banker with Jefferies &
Company, Vector Securities and
Kidder, Peabody & Co.
Founder & Principal, Channel
Medical Partners
Involvement in well over 150
transactions across all sectors
of medical technology industry
Extensive background in both
investment banking and venture
industries

7

Victor Culiuc
Responsible for the Healthcare
Technology and Services
Joined Healthios in 2008
Prior experience includes:
• Credit Suisse (M&A and then
Global Industrials and
Services Group)
• International Monetary Fund
(IMF) in Washington DC
Advised a diverse universe of
clients on M&A and financing
assignments, including mergers,
acquisitions, commercialization
and partnering agreements as
well as private placements
Significant deal execution
experience across all healthcare
sectors
MBA, University of Chicago
Booth School of Business

8

9

2015: Global Healthcare Capital Markets

S T R A T E G I C P AR T N E R I N G P AT H WAY

Healthcare’s Investment Bank

HealthiosXchange for Strategic Partners

S T R A T E G I C P AR T N E R I N G P AT H WAY

PHASE 1:
Sector
Development

PHASE 2:
Positioning

Healthcare’s Investment Bank

PHASE 3:
Engagement

PHASE 4:
Relationship

PHASE 4:
Data
Analytics

PHASE 5:
Growth

HealthiosXchange for Strategic Partners
PHASE 1:
Sector
Development

Selecting Sectors. Assembling EcoSystems. Aggregating Content.

PHASE 2:
Positioning

Establishing Thought Leadership, Strategic Priorities & Process

PHASE 3:
Engagement

Building Dialogue with Broad Universe of Targets

PHASE 4:
Relationship

Solidifying Commitments with Priority Opportunities

PHASE 4:
BIG
Data

Trending. Predictions. Sentiment Analysis. Opinion Marking.

PHASE 5:
Growth

Taking Action.

Healthcare’s Investment Bank

HealthiosXchange for Strategic Partners
PHASE 1:
Sector
Development

PHASE 2:
Positioning

PHASE 3:
Engagement

PHASE 4:
Relationship

PHASE 4:
BIG
Data

PHASE 5:
Growth

Selection &
Segmentation

Strategic Page

Custom Content

Targeting &
Tracking

18 million Data
Points

Opportunity
Origination

Assembling
EcoSystems

Communities &
Groups

Notifications

Messaging &
Alerts

3,000 Concurrent
Experiments

Site Visits

Company
Listings

Clinical &
Market Research

Private / Public
Valuations

“Grand Rounds”
WebCast

Trending &
Activity Scores

Due Diligence

Presentations &
O/M

Sector Pages

“Xchange Live”
Hosted Chat

“Shark Tank”

Milestones &
Inflection Points

LOI

Clinical /
Market Data

Xchange
“LifeLines”

Ratings &
Reviews

Xchange
Conferences

Sentiment &
Prediction

Tagging

Integrated Social
Media

Expert Opinion
WebCasts

Healthcare’s Investment Bank

PHASE 1: Sector Development
Segmentation &
&
Segmentation
Selection
Selection

Assembling
EcoSystems

Company
Listings

Presentations &
O/M
Clinical /
Market Data

Tagging

Healthcare’s Investment Bank

PHASE 2: Positioning
Strategic Page
Page
Strategic

Communities &
Groups

Clinical &
Market Research

Sector Pages

Xchange
“LifeLines”

Integrated Social
Media

Healthcare’s Investment Bank

Phase 3: Engagement
CustomContent
Content
Custom

Notifications

Private / Public
Valuations

Matching &
GeoLocation

Ratings &
Reviews

WebCasts &
Chat

Healthcare’s Investment Bank

Phase 4: Relationships
Targeting &
&
Targeting
Tracking
Tracking

Messaging &
Alerts

“Grand Rounds”
WebCast

“Shark Tank”

Xchange
Conferences

Healthcare’s Investment Bank

Phase 5: BIG Data
18 million
million Data
Data
18
Points
Points

Type of
of event?
event?
Type
When
is
it
going
to happen?
happen?
When is it going to
How big
big will
will itit be?
be?
How

Target/Issuer

3,000 Concurrent
Experiments

The actual
actual number
number
The
of months
months before
before
of
the next
next
the
transaction
11.
transaction isis 11.
Wepredicted
predicted 10.
10.
We

Trending &
Activity Scores

Milestones &
Inflection Points

The actual
actual
The
number of
of
number
months before
before
months
the
next
the next
transaction isis 4.
4.
transaction
We
predicted
3.
We predicted 3.

Sentiment &
Prediction

Healthcare’s Investment Bank

Sector
State
Country
T1_Type
T1_Total_Value
Months from T1 and T2
T2_Type
T2_Total_Value
Months from T2 and T3
T3_Type
T3_Total_Value

Next Transaction value
(ORIGINAL)
Next Transaction value
(PREDICTED)
Prediction confidence

Noveko
International Inc.
Diagnostic Imaging
Quebec
Canada
Private Placement
2.41
13
Private Placement
2.68
8
Private Placement
1.89

21.65
21.65
0.9106

The actual
actual value
value of
of the
the next
next transaction
transaction isis $21.65
$21.65
The
million and
and we
we predicted
predicted $21.65
$21.65 million.
million.
million

Merger and
and acquisition
acquisition
Merger
prediction.
Note that
that
prediction. Note
confidence isis aa bit
bit smaller
smaller
confidence
than
1.
than 1.

The actual
actual value
value of
of the
the next
next
The
transaction isis $150
$150 million
million
transaction
and
we
predicted
$150
and we predicted $150
million.
million.

Phase 6: Growth
Opportunity
Opportunity
Origination
Origination

Site Visits

Due Diligence

INSPIRATION
BIOPHARMACEUTICALS, INC.
Completed a strategic partnership with

$259,000,000
THE UNDERSIGNED ACTED AS EXCLUSIVE
FINANCIAL ADVISOR TO INSPIRATION

LOI

Healthcare’s Investment Bank

HealthiosXchange for Strategic Partners
PHASE 1:
Sector
Development

PHASE 2:
Positioning

PHASE 3:
Engagement

PHASE 4:
Relationship

PHASE 4:
Data
Analytics

PHASE 5:
Growth

Selection &
Segmentation

Strategic Page

Xchange
“LifeLines”

Targeting &
Tracking

18 million Data
Points

Opportunity
Origination

Assembling
EcoSystems

Communities &
Groups

Notifications

Messaging &
Alerts

3,000 Concurrent
Experiments

Site Visits

Company
Listings

Clinical &
Market Research

Private / Public
Valuations

“Grand Rounds”
WebCast

Trending &
Activity Scores

Due Diligence

Presentations &
O/M

Sector Pages

“Xchange Live”
Hosted Chat

“Shark Tank”

Milestones &
Inflection Points

LOI

Clinical /
Market Data

Xchange
Timeline

Ratings &
Reviews

Xchange
Conferences

Sentiment &
Prediction

Tagging

Integrated Social
Media

Expert Opinion
WebCasts

Company
Profile

Strategic
Profile

Going
Social

Healthcare’s Investment Bank

Taking
Action

Deal
Selection

Close

Global Medtech & Pharmaceutical Industry
Capital Flow Analysis

Healthcare’s Investment Marketplace

Global Medtech & Pharmaceutical Industry

Companies are trading at 94%% of their 52 week high
Valuations are at 14.4x EBITDA and 5.1x revenue for 4.4% growth and 74% margins
Large deltas between Forward P/E and TEV/EBITDA indicate high growth expectations in
the stock by investors via organic or inorganic growth

Data generated from Capital IQ

THE Healthcare Merchant Bank

Global Medtech & Pharmaceutical Industry

Historically active investors and acquirers may not continue to be active
Companies with successful IPOs represent new currency in the market

THE Healthcare Merchant Bank

Sponsor Documents

Or use your account on DocShare.tips

Hide

Forgot your password?

Or register your new account on DocShare.tips

Hide

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close